Boehringer Ingelheim and Eli Lilly’s Empagliflozin Receive FDA’s Fast Track Designation for Chronic Heart Failure

Boehringer Ingelheim and Eli Lilly’s Empagliflozin Receive FDA’s Fast Track Designation for Chronic Heart Failure

Shots:

  • The Fast Track designation follows two P-III EMPEROR-Reduced & EMPEROR-Preserved studies assessing Empagliflozin (qd) vs PBO in 8,500+ patients with heart failure with reduced & preserved ejection fraction, both with/without diabetes prior treated with SOC respectively
  • The two P-III EMPEROR-Reduced & Preserved studies will evaluate the safety & efficacy of empagliflozin with the 1EPs as the reduction in risk of cardiovascular death and hospitalization for heart failure with their expected completion in 2020
  • Jardiance (empagliflozin,qd) is an oral therapy used to lower the blood sugar level in adults with T2D and cardiovascular diseases and is contraindicated in patients with T1D and diabetic ketoacidosis

Click here to read full press release/ article | Ref: Eli Lilly | Image: BPDA